AIT Therapeutics Inc. announced positive data at Day 81, the end of its NO-NTM Abscessus clinical trial. The Company previously announced positive preliminary data through Day 51. All patients in the trial were refractory to the standard-of-care for NTM abscessus (MABSC) and had underlying cystic fibrosis. Patients were treated with inhaled NO in addition to background antibiotic therapy at the physicians discretion. NO was delivered at a concentration of 160ppm for 30 minutes intermittently for 21 days (5 times a day for 14 days and then 3 times per day for a subsequent 7 days), after which no further NO treatments were provided. As per the protocol, all patients were followed for 81 days.